PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective.

Autor: Yanev, I.1 (AUTHOR), Aprikian, A.2 (AUTHOR), Raizenne, B.L.3 (AUTHOR), Dragomir, A.4 (AUTHOR)
Zdroj: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS202-S202. 1p.
Databáze: Academic Search Ultimate
Externí odkaz: